The life expectancy of people with cystic fibrosis (CF), a lethal inherited disease, has been greatly extended by advances in therapy. Currently, there are a number of potential drugs for treatment of CF lung disease in clinical trials. These therapies are targeted at all points in the pathogenesis of lung disease, from gene transfer to drugs that treat mucus, infection and inflammation in the airways. An exciting development is that of modulation of the abnormal protein that causes CF, the cystic fibrosis transmembrane conductance regulator (CFTR), where drugs are targeted at specific defects in CFTR transcription, processing or functioning. Inhaled therapies are being developed to augment airway surface liquid height, either by modulating the abnormal ion channel function in the airway epithelial cell or by rehydrating with osmotic agents. Anti-inflammatory therapy is also of great interest in CF and there are several candidate drugs in clinical trials. A number of antibacterial agents formulated for inhalation are at various stages of study or newly approved, which should improve options for chronic management of airway infection. Hopefully, many of these potential therapies will come to market and will further extend the life expectancy of people with CF.
Ashlock, M.A., Beall, R.J., Hamblett, N.M., Konstan, M.W., Penland, C.M., Ramsey, B.W. et al. (2009) A pipeline of therapies for cystic fibrosis. Semin Respir Crit Care Med30: 611-626.
2.
Boyle, M.J. ( 2007) Adult cystic fibrosis. J Am Med Assoc298: 1787-1793.
3.
Chuchalin, A., Csiszer, E., Byurkovics, K., Bartinicka, M.T., Sands, D., Kaproanov, N. et al. (2007) A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs9(Suppl 1): 21-31.
4.
Clancy, J.P. ( 2009) Clinical trials of lipid-associated aerosolized amikacin: the ArikaceTM story (abstract). Pediatr Pulmonol32(Suppl): 186-187.
5.
Clancy, J.P., Rowe, S.M., Durie, P., Freedman, S., Dong, Q., Ordonez, C. et al. (2009) NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator (abstract). Pediatr Pulmonol32(Suppl): 288.
6.
Cystic Fibrosis Foundation (2009) Cystic Fibrosis Foundation Patient Registry 208 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation.
7.
Donaldson, S.H., Bennett, W.D., Zeman, K.L., Knowles, M.R., Tarran, R. and Boucher, R.C. ( 2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med354: 241-250.
8.
Eigen, J., Rosenstein, B.J., Fitzsimmons, S. and Schidlow, D.V. ( 1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr126: 515-523.
9.
Elkins, M., Robinson, M., Rose, B., Harbour, C., Moriarty, C., Marks, G. et al. (2006) National hypertonic saline in cystic fibrosis (NHSCF) study group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med354: 229-240.
10.
Fiel, S.B. ( 2008) Aerosolized antibiotics in cystic fibrosis: current and future trends. Expert Rev Resp Med2: 479-487.
11.
Flume, P.A., O’Sullivan, B.P., Robinson, K.A., Goss, C.H., Mogayzel, P.J., Willey-Courand, D.B. et al. (2007) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med176: 957-969.
12.
Griesenbach, U., Geddes, D.M. and Alton, E.W. ( 2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther13: 1061-1067.
13.
Hirawat, S., Welch, E.M., Elfring, G.L., Northcutt, V.J., Paushkin, S., Hwang, S. et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers . J Clin Pharmacol47: 430-444.
14.
Jacques, A., Daviskas, E., Turton, J.A., McKay, K., Cooper, P., Stirling, R.G. et al. (2008) Inhaled mannitol improves lung function in cystic fibrosis. Chest133: 1388-1396.
15.
Kellerman, D., Mospan, A.R., Engels, J., Schaberg, A., Gorden, J. and Smiley, L. ( 2008) Denufosol: a review of studies with inhaled P2Y2 agonists that led to phase 3. Pulm Pharmacol Ther21: 600-607.
16.
Kerem, E., Bauer, S., Strauss, P., Jaffe, N., Armoni, S., Pugatsch, T. et al. (2009) Safety and efficacy of inhaled human alpha-1 antitrypsin in CF: a report of a phase II clinical study. Pediatr Pulmonol32(Suppl): 303 (abstract).
17.
Kerem, B., Chiba-Falek, O. and Kerem, E. ( 1997) Cystic fibrosis in Jews: frequency and mutation distribution . Genet Test1: 35-39.
18.
Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M. et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet372: 719-727.
19.
Konstan, M.W., Byard, P.J., Hoppel, C.I. and Davis, P.B. ( 1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med332: 848-854.
20.
Kunzelmann, K. and Mall, M. ( 2003) Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics . Am J Respir Med2: 299-309.
21.
Lands, L.C., Milner, R., Cantin, A.M., Manson, D. and Corey, M. ( 2007) High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr151: 249-254.
22.
Li, Z., Zhang, Y., Wurtz, W., Lee, J.K., Malinin, V.S., Durwas-Krishnan, S. et al. (2008) Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv21: 245-254.
23.
Lommatzsch, S.T. and Aris, R.(2009) Genetics of cystic fibrosis. Semin Respir Crit Care Med30: 531-538.
24.
Lubamba, B., Lecourt, H., Lebacq, J., Lebecque, P., De Jonge, H., Wallemacq, P. et al. (2008) Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Resp Crit Care Med177: 506-515.
25.
Machen, T.E. ( 2006) Innate immune response in CF airway epithelia: hyperinflammatory ? Am J Physiol Cell Physiol291: C218-C230.
26.
Martin, S.L., Downey, D., Bilton, D., Keogan, M.R., Edgar, J. and Elborn, J.S. ( 2006) Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol41: 177-183.
27.
McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z. and Montgomery, A.B. ( 2008) Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med178: 921-928.
28.
Moss, R.B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P.L., Clancy, J.P. et al. (2007) Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gen Ther18: 726-732.
Pickles, R.J. ( 2004) Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thorac Soc1: 302-308.
31.
Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J. et al. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med340: 23-30.
32.
Ratjen, F.A. ( 2006) Restoring airway surface liquid in cystic fibrosis. N Engl J Med354: 291-293.
Retsch-Bogart, G.Z., Quittner, A.L., Gibson, R.L., Oermann, C.M., McCoy, K.S., Montgomery, A.B. et al. (2009) Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest135: 1223-1232.
35.
Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z. et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science245: 1066-1073.
36.
Rowe, S.M., Miller, S. and Sorscher, E.J. ( 2005) Cystic fibrosis. N Engl J Med352: 1992-2001.
37.
Sly, P.D., Brennan, S., Gangell, C., de Klerk, N., Murray, C., Mott, L. et al. (2009) Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med180: 146-152.
38.
Tirouvanziam, R., Conrad, C.K., Bottiglieri, T., Herzenberg, L.A., Moss, R.B. and Herzenberg, L.A. ( 2006) High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A103: 4628-4633.
39.
Tirouvanziam, R., de Bentzmann, S., Hubeau, C., Hinnrasky, J., Hinnrasky, J., Jacquot, J. et al. (2000) Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol23: 121-127.
